Join The Rezolution
Dedicated to supporting those impacted by frequent and severe hypoglycemia related to hyperinsulinism
Our commitment to the hyperinsulinism community runs deep. We strive to better understand the daily challenges and emotional journey that patients and caregivers face, and we’re committed to providing meaningful support every step of the way.
That’s why we’re proud to introduce The Rezolution, an initiative that offers updates on therapy innovations, information on community events, and educational support.
We believe progress comes through partnership—empowering families, fostering connections, and moving forward together in a shared rezolution for better care and brighter futures.
Partnering with Patient Organizations
We are proud to support and collaborate with the patient advocacy organizations that serve as lifelines for families affected by congenital hyperinsulinism (cHI) and tumor hyperinsulinism.
The organizations below were each founded by caregivers and patients whose lives have been impacted by hyperinsulinism, and they play a vital role in connecting their respective communities to education, research, clinical care, and support. Their work informs and inspires our own, and we are honored to stand alongside them in advancing their mission and amplifying their impact.
Understanding HI
Congenital Hyperinsulinism
Tumor Hyperinsulinism
Rezolute Reflections
As you and your family navigate life with HI, our Patient Affairs team is here to walk alongside you every step of the way. We look forward to the opportunity to provide updates on therapy innovations, educational resources, and meaningful connections.
Dana Jastrow
Director of Patient Affairs
Dana Jastrow serves as the Director of Patient Affairs at Rezolute, where she leads initiatives designed to engage, empower, and support rare-disease communities. She focuses on building trusted relationships with patients, caregivers, advocacy groups, and external partners to ensure that the lived experiences of those affected are meaningfully integrated into the company’s work. Dana began her career in the nonprofit sector before moving into the pharmaceutical industry, motivated by a strong commitment to connect patient voices with scientific innovation. With a deep appreciation for the challenges faced by rare-disease families, she works to make sure their perspectives guide the development of new therapies, particularly in areas where treatment options remain limited. As Rezolute prepares for commercialization, Dana plays a vital role in shaping inclusive, collaborative partnerships that keep patients at the center of the company’s mission. She welcomes connection with the hyperinsulinism community and invites anyone interested in Rezolute’s progress to reach out to her directly by email at patient-affairs@rezolutebio.com.
Dr. Davelyn Eaves Hood
Vice President of Medical and
Patient Affairs
Dr. Davelyn Eaves Hood is the Vice President of Medical and Patient Affairs, where she unites her professional life as a physician with her personal experience as the mother of a child—now an adult—born with severe, diffuse congenital hyperinsulinism. This dual perspective gives her a unique understanding of the challenges, frustrations, and emotional toll faced by patients, families, and healthcare providers in managing this rare, life-threatening disease. Her professional career has included leadership roles spanning clinical practice, healthcare administration, and payer settings, and for nearly a decade prior to joining Rezolute, she dedicated many hours of volunteer time to Congenital Hyperinsulinism International (CHI), serving seven years as Board President. During this time with the international patient advocacy organization, Davelyn helped shape and launch cornerstone initiatives, such as the HI Global Registry and the CHI Centers of Excellence program. Through close collaboration with families, advocates, and clinicians around the world, she strived to ensure that patient perspectives guided these efforts, helping to increase disease awareness, expand patient-centered research, and improve care for the global cHI community—values she continues to bring to drug development at Rezolute.
Events Calendar
Looking for therapy updates, information on upcoming events, and a behind-the-scenes look at what’s happening at Rezolute? Click below to view our monthly newsletter, The Rezolution Report, or register to receive it monthly via email.
Want to learn more about cHI? Take a look at our Patient Presentations & Publications archive.
Patient Presentations & Publications Archives
About Ersodetug
Ersodetug is an insulin receptor modulating antibody, a type of treatment created using the body’s own targeting system to attach to the side of the insulin receptor (a part of your cells that helps control blood sugar) and makes it harder for certain proteins, like insulin or insulin-like growth factor 2 (IGF-2), to lower blood sugar too much. This action may help keep blood sugar levels in a more stable, healthier range.
Compassionate Use
When no approved treatments are available, some patients may qualify for Compassionate Use, also called an Expanded Access Program (EAP). Rezolute supports EAPs to help patients with serious conditions access investigational therapies like ersodetug. An investigational therapy is one that is being studied but has not yet been approved for any use by any health authority.
Our EAP is designed for patients who benefited from ersodetug during clinical trials and wish to continue treatment, or for those with severe, frequent low blood sugar due to high insulin levels who have no other options.
If you think you may qualify, talk to your healthcare provider or contact us at medical-affairs@rezolutebio.com.
Join The Rezolution
Be a part of the movement. Complete this form to stay up to date on therapy innovations, events, and educational resources.
Ersodetug is an investigational drug candidate. The FDA has not determined that ersodetug is safe or effective. No indication(s), warnings, precautions, adverse reactions, dosage or administration information for ersodetug have been approved by the FDA. This video depicts the favorable results of ersodetug use for a single patient. It is not intended to guarantee or promote that ersodetug will provide similar results for other subjects participating in the ersodetug Phase III clinical trial or Expanded Access Program.
This video, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “prove,” “potential,” “seek,” “strive,” “try,” or future or conditional verbs such as “predict,” “could,” “may,” “likely,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Viewers are cautioned not to place undue reliance on these forward-looking statements, which speak only as an individual patient. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov.
You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. This video shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.